New world-leading facility for UCL Neuroscience gains planning approval

UCL is delighted to announce that conditional planning permission* has been granted for a new £281.6m state-of-the-art facility, which will be home to UCL Neuroscience. The plans will transform the site at 256 Gray's Inn Road, London, bringing together research scientists, clinicians and patients to create a world-leading hub for dementia and neurological disease research. UCL is a global leader in pioneering research into neurological diseases such as Alzheimer's disease, multiple sclerosis, Huntington's disease, n euromuscular diseases,  Parkinson's disease, motor neurone disease, stroke and epilepsy. The new facility will create a collaborative, interdisciplinary environment to translate UCL's research power into developing treatments for these conditions. The site, which currently comprises the Eastman Dental Hospital**, the former Royal Free Hospital, the UCL Eastman Dental Clinic and the Levy Wing, is part of a major redevelopment project and will house over 500 neurological research scientists from UCL Queen Square Institute of Neurology and the UK Dementia Research Institute (UK DRI), along with the UK DRI national headquarters. The building will also house outpatient consulting and an MRI suite for the UCLH National Hospital for Neurology and Neurosurgery. Professor Alan Thompson, Dean of Faculty of Brain Sciences and Garfield Weston Professor of Clinical Neurology and Neurorehabilitation, said: "We are delighted Camden Council has approved these plans, which will ensure this historic site remains at the heart of London's cutting-edge health and science communities.